J&J JNJ stock has plunged 6.1% in a month, losing almost $24 billion of its market value.Though slowing sales in its MedTech segment, the upcoming patent expiration of its blockbuster drug, Stelara, and...
KVUE earnings call for the period ending September 30, 2024.
/CNW/ - Kenvue Canada Inc., a division of Kenvue Inc. (NYSE: KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue and maker of...
Kenvue has lagged the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.
Can tinkering around the edges actually make this stock more attractive?
While tech-based growth stocks might seem like the right play, you can't ignore dividends if you want to have a strong portfolio.
Ken Griffin's Citadel just added 18 million shares of an under-the-radar consumer health stock.
An activist investor is taking a stake in Kenvue stock.
The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.